<DOC>
	<DOCNO>NCT02946671</DOCNO>
	<brief_summary>To assess safety preoperative combination therapy KW-0761 ( anti-CCR4 ) ONO-4538 ( anti-PD-1 ) . To assess behavior immune cell peripheral blood tumor .</brief_summary>
	<brief_title>Study Pre-operative Combination Therapy With Mogamulizumab Nivolumab Against Solid Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients enable standard operation Patients refuse standard preoperative chemotherapy diagnose follow cancer ; gastric adenocarcinoma , esophageal squamous cell carcinoma , nonsmallcell lung carcinoma renal cell carcinoma Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients serious disorder major organ ( bear marrow , heart , lung , liver kidney ) Patients write informed consent Patients measurable target lesion Patients enable undergo biopsy sample tumor tissue Known previous autoimmune disease Known suspect interstitial lung disease ( ILD ) Patients history serious anaphylaxis induce antibody preparation Uncontrollable hypertension Uncontrollable endocrine disease Patients active inflammatory bowel disease serious GI chronic condition associate diarrhea Uncontrollable diabetes Prior therapy sustain anticancer agent , radiotherapy surgery primary disease Pregnant lactating female , female male patient agree practice adequate birth control consent study Known suspect infection inflammatory disease Prior therapy hematopoietic stem cell transplantation Known suspect central nervous system ( CNS ) involvement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>